Neoantigen mRNA Vaccines Market Outlook 2026–2036: Market Size, Growth Drivers, Key Players, Strategic Developments & Adoption Forecast for Individualized Neoantigen Therapies, Intismeran Autogene, Autogene Cevumeran, Checkpoint Combinations, Personalized Manufacturing and Reimbursement — A Meticulous Next™ Foresight Brief

This Meticulous Next™ brief examines how personalized neoantigen mRNA cancer vaccines — therapies designed for one patient from the mutations in that patient's own tumour, encoding up to several dozen neoantigens in mRNA and given alongside checkpoint inhibitors to prevent recurrence after surgery — will move from trials into oncology practice over the next ten years. The field reached its decisive moment in August 2026, when Merck and Moderna reported that the 1,137-patient phase 3 INTerpath-001 trial of intismeran autogene plus pembrolizumab met its primary endpoint of recurrence-free survival and its key secondary endpoint of distant metastasis-free survival in resected stage IIB–IV melanoma — the first phase 3 success for an individualized cancer vaccine, following five-year phase 2b data showing a 49% reduction in risk of recurrence or death and a 59% reduction in risk of distant metastasis or death. The World Economic Forum ranked personalized mRNA cancer vaccines seventh among its top ten emerging technologies of 2026. The same month, BioNTech terminated its phase 2 trial of autogene cevumeran as adjuvant monotherapy in ctDNA-positive colorectal cancer on a data monitoring board recommendation, while its pancreatic cancer combination trial continues — a reminder that indication, combination and patient selection decide outcomes. Moderna's purpose-built Marlborough plant has supplied clinical batches since September 2025, and three phase 3 trials in melanoma and non-small cell lung cancer, five phase 2 trials and the NHS Cancer Vaccine Launch Pad in the United Kingdom are enrolling. The brief maps the technology, its indicative market size and forecast, the factors behind its growth, the developments of the last 24 months, the key players operating in the space and the adoption trajectory to 2036.

It is a focused 108-page decision brief for pharmaceutical and biotechnology companies, oncology centres and health systems, payers and health technology assessment bodies, sequencing, manufacturing and logistics providers, regulators and investors. It presents an indicative trajectory rather than a segmented market model. Its purpose is to identify which indications and combinations reach approval first, how manufacturing, pricing and reimbursement change the pace, and who captures the resulting value.

A personalized neoantigen mRNA vaccine starts with the patient's tumour. Tumour and normal tissue are sequenced, the mutations unique to the cancer are identified, and an algorithm predicts which of the resulting neoantigens the patient's immune system — given their HLA type — is most likely to recognise. Up to 34 of those neoantigens are encoded in a single mRNA, which is manufactured for that one patient, formulated in lipid nanoparticles and injected in a course of up to nine doses alongside a checkpoint inhibitor. The vaccine trains T cells against the patient's own tumour mutations; the checkpoint inhibitor removes the brakes. The approach is used after surgery, when residual disease is microscopic and the immune system can clear it, which is why the endpoints are recurrence-free and distant metastasis-free survival.

The evidence now spans phases. Moderna and Merck's intismeran autogene (mRNA-4157, V940) plus pembrolizumab reduced the risk of recurrence or death by 49% and of distant metastasis or death by 59% over five years in the phase 2b KEYNOTE-942 trial, and the 1,137-patient, double-blind phase 3 INTerpath-001 trial met both endpoints at its planned interim analysis in August 2026 with no new safety signals, with overall survival still maturing. The programme has three phase 3 trials — adjuvant melanoma and adjuvant non-small cell lung cancer in two settings — and five phase 2 trials in renal, bladder, metastatic melanoma and squamous lung cancer. BioNTech and Genentech's autogene cevumeran showed in pancreatic cancer that vaccine-induced T cells correlate with delayed recurrence, and its phase 2 combination trial in that indication continues; its colorectal monotherapy trial was stopped in August 2026 after an overall-survival imbalance, ten months after crossing a futility boundary.

The constraints are manufacturing, time, cost and selection. Each product is a batch of one: sequencing, prediction, synthesis, fill and release testing take a few weeks on Moderna's automated workflow, and the product must be tracked from biopsy to infusion while the adjuvant treatment window after surgery is open. Production scales out in parallel rather than up, which is why Moderna built the Marlborough plant specifically for intismeran. Unit cost is higher than for conventional biologics and the price will be set against recurrences avoided and the cost of the checkpoint inhibitor partner. And the BioNTech result shows that indication, combination and patient selection — ctDNA status, tumour mutational burden, timing — decide whether a personalized vaccine works. The decade's question is how far beyond melanoma the approach extends.

The personalized neoantigen mRNA vaccine market — development, trial supply, manufacturing build-out and partnership value in 2026, and product sales thereafter — is estimated at USD 0.3–0.5 billion in 2026, led by Moderna and Merck's INTerpath programme, BioNTech and Genentech's autogene cevumeran, individualized manufacturing capacity and sequencing and prediction services. Meticulous Next™ expects it to reach USD 10–14 billion by 2036, an indicative CAGR of 38–42%. Growth is driven by the first approval of intismeran autogene in adjuvant melanoma expected from 2027, by lung cancer phase 3 readouts and approvals around 2029 to 2031, by expansion into renal, bladder and other adjuvant settings, by reimbursement decisions in the United States, Europe and the United Kingdom and by competing programmes reaching phase 3. The market is concentrated in one lead programme in its early years and depends on approval timing and pricing; the delayed case reflects regulatory or manufacturing slippage. The United States leads on approval, manufacturing and uptake; Europe and the United Kingdom lead on early access through the NHS Cancer Vaccine Launch Pad and EMA PRIME; Japan and China develop their own programmes; checkpoint-inhibitor-treated melanoma and lung cancer are the first indications.

The base case assumes intismeran autogene approval in adjuvant melanoma in 2027, lung cancer approvals around 2030 and reimbursement in the main markets by 2029. An accelerated case assumes priority review and early lung cancer success, bringing the inflection to 2028 and lifting the 2036 value to the top of the range. A delayed case assumes regulatory requests for overall survival data, manufacturing or pricing disputes and lung cancer setbacks, pushing the inflection to 2031 and confining the market to melanoma for most of the horizon.

Growth drivers

• Clinical proof: the first phase 3 success for a personalized cancer vaccine in INTerpath-001, on top of five-year phase 2b data showing 49% and 59% risk reductions.
• Unmet need: high recurrence after surgery in stage IIB–IV melanoma and resected lung cancer despite checkpoint inhibitors.
• Checkpoint inhibitor franchises: Merck's pembrolizumab and other PD-1 inhibitors need combination partners as exclusivity approaches.
• Policy and recognition: WEF top ten status, the NHS Cancer Vaccine Launch Pad targeting 10,000 patients by 2030, and FDA breakthrough and EMA PRIME designations.

Enablers

• Purpose-built individualized manufacturing at Moderna's Marlborough site with automated workflows and a turnaround of a few weeks.
• Tumour and germline sequencing and machine-learning neoantigen prediction across up to 34 targets.
• Lipid nanoparticle and mRNA platform experience from infectious disease vaccines.
• Oncology centre pathways and ctDNA assays for patient selection.

Restraints and barriers

• No approval yet; regulators may seek overall survival data and manufacturing comparability.
• Batch-of-one cost, turnaround and chain-of-identity logistics against the adjuvant treatment window.
• Indication and combination risk, shown by the termination of BioNTech's colorectal monotherapy trial.

Pricing and reimbursement for a personalized product added to an expensive checkpoint inhibitor.

Five converging forces will determine how fast, and how far, personalized neoantigen mRNA vaccines enter oncology practice: (1) phase 3 results and regulatory decisions; (2) individualized manufacturing scale and turnaround; (3) pricing and reimbursement; (4) expansion to lung cancer and other indications with the right combinations and patient selection; and (5) competing programmes and checkpoint inhibitor dynamics. The brief assesses each force for direction, speed and confidence.

The key players operating in personalized neoantigen mRNA vaccines include Moderna, Inc., Merck & Co., Inc., BioNTech SE, Genentech, Inc. (F. Hoffmann-La Roche Ltd), CureVac N.V., Transgene SA, Nouscom AG, Nykode Therapeutics ASA, Evaxion Biotech A/S, Imvax, Inc., Geneos Therapeutics, Inc., Elicio Therapeutics, Inc., Agenus Inc., Vaccitech plc (Barinthus Biotherapeutics), Neon Therapeutics heritage programmes, Shanghai Junshi Biosciences Co., Ltd., CSPC Pharmaceutical Group Limited, Stemirna Therapeutics Co., Ltd., Daiichi Sankyo Company, Limited, Bristol-Myers Squibb Company, AstraZeneca PLC, Pfizer Inc., Illumina, Inc., Thermo Fisher Scientific Inc., Tempus AI, Inc., Caris Life Sciences, Inc., Personalis, Inc., Guardant Health, Inc., Natera, Inc., Lonza Group AG, Samsung Biologics Co., Ltd., Catalent, Inc., TriLink BioTechnologies (Maravai LifeSciences Holdings, Inc.), Acuitas Therapeutics, Inc., Cryoport, Inc., NHS England and Genomics England. The brief profiles representative players in each archetype and assesses which are positioned to bring personalized vaccines to patients at scale.

The competitive landscape is forming around six archetypes. First-mover developers with phase 3 programmes. Follow-on neoantigen vaccine developers on mRNA and other platforms. Checkpoint inhibitor and large pharma partners. Sequencing, neoantigen prediction and ctDNA companies. Individualized manufacturing, mRNA supply and cold-chain logistics providers. Oncology centres, health systems and payers. Competitive intensity is concentrated in 2026 around one lead programme and is expected to broaden as follow-on programmes reach phase 3 through 2030.

Where value migrates.

In 2026 value sits in the INTerpath programme, individualized manufacturing build-out, sequencing and prediction services and partnership value. By 2029 it moves to the approved product in adjuvant melanoma and its checkpoint partner, commercial individualized manufacturing, oncology-centre pathways and reimbursement in the first markets. By 2036 it settles in the first-mover programme and follow-on developers with approved products across melanoma, lung and other cancers, manufacturing and logistics providers, sequencing and ctDNA companies and the health systems that built the pathway early. Monotherapy and poorly selected programmes lose ground, as the BioNTech colorectal result showed.

Capital is concentrated in two partnerships — Moderna and Merck sharing development, commercialisation and profits equally on intismeran autogene, and BioNTech and Genentech on autogene cevumeran — with Moderna's Marlborough plant the first purpose-built individualized oncology manufacturing site and the NHS Launch Pad the largest public access programme. Follow-on developers in Europe, the United States and China are funding phase 1–2 programmes on mRNA, viral vector, peptide and DNA platforms. Patent and research activity is concentrated in neoantigen prediction algorithms, HLA-binding models, mRNA design and lipid nanoparticle formulation, automated parallel manufacturing and ctDNA-based patient selection. The brief tracks four indicators: regulatory filings and decisions for intismeran autogene, lung cancer phase 3 readouts, individualized manufacturing turnaround and capacity, and reimbursement decisions.

The United States leads on approval, manufacturing and uptake through Moderna, Merck and the FDA. Europe and the United Kingdom lead on early access and evidence through the NHS Launch Pad, EMA PRIME and BioNTech. Japan and China develop their own programmes and manufacturing. Adjuvant melanoma is the first indication; non-small cell lung cancer is the second and largest; renal, bladder and pancreatic cancer follow.